- Conditions
- Thyroid Nodule, Thyroid Cancer, Thyroid Diseases, Thymic Carcinoma
- Interventions
- Not listed
- Lead sponsor
- Aventura Hospital and Medical Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Aventura, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 61
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mesolthelioma, Esophageal Cancer, Lung Cancer, Thoracic Sarcomas, Thymoma
- Interventions
- Celebrex, Tumor cell vaccine
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Thymic Carcinoma
- Interventions
- Milciclib Maleate
- Drug
- Lead sponsor
- Tiziana Life Sciences LTD
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Bethesda, Maryland
- Conditions
- Thymoma, Stomach Neoplasms, Pancreatic Neoplasms, Mesothelioma, Biliary Tract Neoplasms, Mesothelin Expressing Neoplasms
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Recurrent Malignant Thymoma, Thymoma
- Interventions
- Diaphragm Fluoroscopy, Magnetic Resonance Imaging
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms
- Interventions
- KFA115, pembrolizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Thymoma, Thymic Carcinoma
- Interventions
- Belinostat (PDX101)
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Bethesda, Maryland
- Conditions
- Thymic Cancer, Thymoma
- Interventions
- bevacizumab, Erlotinib
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Thymic Carcinoma, Non-small Cell Lung Cancer, Refractory Thoracic Tumors, Small-Cell Lung Cancer
- Interventions
- Vorolanib, Nivolumab
- Drug · Biological
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 7
- States / cities
- Palo Alto, California • Atlanta, Georgia • Chicago, Illinois + 4 more
- Conditions
- Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Ovarian Neoplasms, Lung Neoplasms, Thymus Neoplasms, Colonic Neoplasms
- Interventions
- cyclophosphamide, fludarabine, TNhYP218 CAR T Cells, mesothelin expression testing
- Drug · Biological · Device
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2044
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Thymoma, Thymic Carcinoma
- Interventions
- PXD101with cisplatin+doxorubicin+cyclophosphamide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinoma, Renal, Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Carcinoma, Neuroendocrine, Carcinoma, Thymic, Carcinoma, Pancreatic, Carcinoma Breast, Carcinoma, Ovarian, Carcinoma Bladder, Carcinoma of Unknown Primary, Carcinoma of the Head and Neck, Carcinoma of the Oropharynx, Carcinoma of the Larynx, Carcinoma of the Bladder, Carcinoma of Esophagus, Carcinoma of the Nasopharynx, Carcinoma of the Penis, Carcinoma of the Cervix, Carcinoma of the Anus, Carcinoma of the Vulva, Carcinoma of the Appendix, Carcinoma of the Oral Cavity, Cholangiocarcinoma, Melanoma, Mesothelioma, Pancreatic Cancer
- Interventions
- Not listed
- Lead sponsor
- Travera Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Thymoma, Thymic Carcinoma
- Interventions
- Avelumab
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Stage III Thymoma AJCC v8, Stage IIIA Thymoma AJCC v8, Stage IIIB Thymoma AJCC v8, Stage IV Thymoma AJCC v8, Stage IVA Thymoma AJCC v8, Stage IVB Thymoma AJCC v8, Unresectable Thymic Carcinoma
- Interventions
- Pembrolizumab
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Thymic Carcinoma
- Interventions
- KN046
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Esophageal Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Lymphoma, Mesothelioma, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Pleura, Metastatic Malignant Neoplasm in the Spinal Cord, Non-Small Cell Lung Carcinoma, Sarcoma, Small Cell Lung Carcinoma, Thymic Carcinoma, Thymoma, Thyroid Gland Carcinoma
- Interventions
- Doxepin Hydrochloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 3
- States / cities
- Rochester, Minnesota • Omaha, Nebraska • Green Bay, Wisconsin
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma
- Interventions
- XmAb20717
- Biological
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 17
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 12 more
- Conditions
- Invasive Thymoma and Thymic Carcinoma, Recurrent Thymoma and Thymic Carcinoma, Stage III Thymoma, Stage IVA Thymoma, Stage IVB Thymoma
- Interventions
- saracatinib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 2
- States / cities
- Stanford, California • Indianapolis, Indiana
- Conditions
- Candidiasis, Chronic Mucocutaneous
- Interventions
- Amphotericin B
- Drug
- Lead sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Malignancy, Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Testicular Cancer, Thymoma, Ovarian Cancer, Osteosarcoma
- Interventions
- palifosfamide-tris
- Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Lafayette, Indiana • Muncie, Indiana + 1 more
- Conditions
- Thymoma, Thymus Cancer, Thymic Carcinoma
- Interventions
- Amrubicin
- Drug
- Lead sponsor
- Heather Wakelee
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 2
- States / cities
- Stanford, California • Indianapolis, Indiana
- Conditions
- Cancer
- Interventions
- Fentanyl sublingual spray, Placebo
- Drug
- Lead sponsor
- INSYS Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Chandler, Arizona
- Conditions
- Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III, Esophagogastric Cancer Stage I-III, Thymoma and Thymic Carcinoma Stage II-III, Other Cancers in the Thoracic Region
- Interventions
- MRgART, LINAC
- Radiation
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Lung Cancer, Malignant Mesothelioma, Metastatic Cancer, Thymoma and Thymic Carcinoma
- Interventions
- radiofrequency ablation
- Procedure
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Los Angeles, California